Featured product: FemoSeal™ Vascular Closure System
Schulz-Schüpke et al. Comparison of VCD vs Manual Compression After Femoral Artery Puncture. The ISAR-CLOSURE Randomised Clinical Trial. JAMA, 312(19):1981-1987. 2014.
Randomised controlled multicenter open-label clinical trial with 4.524 patients undergoing coronary angiography with 6 Fr sheath.
After angiography of the access site, patients were randomised to hemostasis with intravascular VCD (FemoSeal; n=1.509), Extravascular VCD (ExoSeal; n=1.506) or manual compression (n=1.509) in 1:1:1 ratio.
Primary endpoint: the composite of access site-related vascular complications at 30 days after randomization with a 2% noninferiority margin.
Secondary endpoints: time to hemostasis, repeat manual compression, and VCD failure.
The primary endpoint was observed in 208 patients (6.9%) assigned to receive a VCD and 119 patients (7.9%) assigned to manual compression (p for non-inferiority <0.001).
Time to hemostasis was significantly shorter in patients with VCD (1 min) vs manual compression (10 min) (p<0.001).
Time to hemostasis was significantly shorter among patients with intravascular VCD (FemoSeal; 0.5 min) vs extravascular VCD (ExoSeal; 2 min) (p <0.001).
Closure device failure was also significantly lower among patients with intravascular vs extravascular VCD (80 patients (5.3%) vs 184 patients (12.2%); p <0.001).
VCD are non-inferior to Manual Compression (vascular access site complications & shorter time to hemostasis, and FemoSeal vs ExoSeal has faster hemostasis, less deployment failures and less complications
Holm N. Randomised comparison of manual compression and FemoSeal™ vascular closure device for closure after femoral artery access coronary angiography: CLOSE-UP Study. EuroIntervention, 9:183-190. 2014.DESCRIPTION
Single center randomised trial, conducted at the Aarhus University Hospital in Denmark.
Objective: compare the safety and efficacy of the FemoSeal VCD vs manual compression after femoral access coronary angiography (CAG).
1001 consecutive patients, 501 patients had a FemoSeal closure device and 500 patients received manual compression.
Primary endpoint: in-hospital incidence of access-site haematoma >5 cm. Secondary endpoints included 14-day major bleeding, retroperitoneal bleeding, pseudoaneurysm, arteriovenous fistula, infection, other complications requiring surgery.
The primary endpoint was observed in 6.7% of the manual compression patients vs 2.2% for FemoSeal group (p=0.002).
Median closure time was 8.0 minutes for manual compression vs 1.0 minute with FemoSeal (p<0.0001).
Closure of femoral access after coronary angiography by FemoSeal was associated with significantly fewer in-hospital large haematomas and was haemostasis was significantly faster.
Jun Jiang et al. Network Meta-analysis of Randomised Trials on the Safety of Vascular Closure Devices for Femoral Arterial Puncture Site Haemostasis. Sci Rep.; 5:13761. 2015.
Objective: Network meta-analysis comparing the safety of different VCDs.
40 RCTs with 16.868 patients
Comparison of different VCDs vs MC with patients undergoing diagnostic and/or interventional femoral procedures
Traditional meta-analysis: no significant difference in the rate of Combined Adverse Vascular Events (CAVEs) between all the VCDs and manual compression (MC)
Traditional meta-analysis: risk for CAVE is similar between VCDs and MC
Subgroup analysis: similar results, but FemoSeal showed significantly reduced risk of CAVE
Haematoma risk: significantly lower with VCDs vs MC (RR: 0.80, CI: 0.71-0.90)
Design improvements of VCDs & increased user experience -> decreases risk of CAVE
Vascular closure devices
N° of studies
Test for overal effect
RR (95% CI)
0.69 [0.46, 1.03]
1.10 [0.75, 1.61]
1.45 [0.55, 3.84]
1.27 [0.48, 3.37]
0.75 [0.60, 0.94]
1.00 [0.65, 1.52]
0.63 [0.29, 1.37]
2. Network analysis on CAVE:
Angio-Seal – reduced risk of CAVE vs MC (RR: 0.67, CI: 0.46–0.98)
Other VCDs: similar risk for CAVE vs MC. No difference in risk for CAVE between different VCDs.
The use of VCDs significantly decreased the risk of haematomas
The newly developed VCDs significantly reduced the rate of CAVE
FemoSeal also significantly reduced the risk of CAVE. Newer VCDs with advanced design might improve the safety of VCDs
Angio-Seal, which might be the best VCD among all included VCDs, reduced the rate of both CAVE and haematomas vs MC
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.